LOGIN  |  REGISTER
Terns Pharmaceuticals

Syra Health to Participate in Upcoming 2024 Healthcare Conferences

December 12, 2023 | Last Trade: US$0.12 0.0071 -5.59

CARMEL, Ind., Dec. 12, 2023 /PRNewswire/ -- Syra Health Corp. (NASDAQ: SYRA) ("Syra Health" or the "Company"), a healthcare technology company with a mission to improve healthcare by providing innovative services and technology solutions, today announced that it will take part in several upcoming healthcare conferences. Leaders from Syra Health will participate in the following:

  • JP Morgan Healthcare Conference, January 8-11, 2024, San Francisco, California
  • ViVE Digital Health Tech Conference, February 25-28, 2024, Los Angeles, California  
  • HIMSS Global Health Conference and Exhibition, March 11-15, Orlando, Florida

Management will be meeting with investors at JP Morgan. If you'd like to schedule a meeting, please reach out Lytham Partners via their contact information below.

ABOUT SYRA HEALTH

Syra Health is a healthcare technology company addressing some of healthcare's most significant challenges in areas such as behavioral and mental health, digital health, and population health, by providing innovative services and technology solutions. Syra Health's products and services are centered on prevention, improved access, and affordable care. Syra Health supplies its solutions to payers, providers, life sciences organizations, academic institutions, and government. For more information, please visit www.syrahealth.com.

For Media Inquiries:
Syra Health
Communications & Marketing Director
Christine Drury
463-345-5180
This email address is being protected from spambots. You need JavaScript enabled to view it.

For Investor Inquiries:
Ben Shamsian
Vice President
Lytham Partners, LLC
646-829-9701
This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Immix Biopharma

Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page